Delcath Systems Raises 2026 Product Revenue Outlook to $115 Million-$117 Million

Delcath Systems Inc. raised its 2026 revenue forecast for HEPZATO KIT and CHEMOSAT to $115 million to $117 million after quarterly sales of both offerings climbed from a year earlier. The full-year outlook reflects expected HEPZATO KIT volume growth of at least 41% over 2025. Delcath also projects gross margins of 87% to 89% and positive adjusted earnings before interest, taxes, depreciation and amortization. Third-quarter revenue reached $35.1 million, up from $20.6 million in the same period of 2025. HEPZATO KIT brought in $32.7 million, compared with $19.3 million a year earlier. CHEMOSAT revenue rose to $2.4 million from $1.3 million. Delcath reported 33 active treatment centers. HEPZATO treatment volume grew approximately 72% from the third quarter of 2025.

BeCrypto News shows a short excerpt and links to the publisher. The full report belongs to TokenPost.